Key Takeaways From the RELIEVE Study of T-DXd in Real-World mBC
Paolo Tarantino, MD, discusses what to know about the real-world findings from the RELIEVE study which were presented at the 2023 San Antonio Breast Cancer Symposium.
Elacestrant in Clinical Practice for Patients with ER+/HER2-Low Metastatic Breast Cancer
Dr. Paolo Tarantino offers expert guidance on optimizing outcomes for patients with ER+/HER2-low metastatic breast cancer.
EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant
A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.
The Evolving Treatment Landscape in ER+/HER2- Low Metastatic Breast Cancer
Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.